Dulac Edward J III

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 2 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

2
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
Intellia Therapeutics, Inc.EVP, Chief Financial OfficerOpen-market sell$91,2498,111 sharesJul 24, 2026Intellia Therapeutics, Inc.EVP, Chief Financial Officer$91,249Sell · Jul 24Open-market sell8,111Jul 24, 2026
Intellia Therapeutics, Inc.EVP, Chief Financial OfficerOpen-market sell$84,1864,677 sharesJul 6, 2026Intellia Therapeutics, Inc.EVP, Chief Financial Officer$84,186Sell · Jul 6Open-market sell4,677Jul 6, 2026